---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-040650"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:39:29.452332+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Roivant unveils mosliciguat, inhaled sGC activator for PH-ILD; Phase 1b shows PVR reduction up to 38%

## Summary
- Phase 1b ATMOS in 38 PH patients: single dose of mosliciguat produced mean-max PVR reduction up to ~38%, exceeding ≥20% threshold.
- Mosliciguat is potential first-in-class, inhaled once-daily sGC activator with targeted lung delivery via dry powder inhaler.
- Global Phase 2 PHocus study in ~120 PH-ILD patients imminent; PH-ILD prevalence ~200,000 in US/Europe with few treatments.
- Roivant in-licensed from Bayer for ~$14M upfront, up to $280M milestones + tiered high-single digit royalties.
- Favorable safety in 170 participants; 40-hour half-life enables once-daily dosing; differentiated from existing therapies.

## SEC filing metadata
- accession: 0001140361-24-040650
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124040650/0001140361-24-040650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124040650/ef20035693_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-040650
- JSON: https://secwatch.observer/filing/0001140361-24-040650.json
- Plain text: https://secwatch.observer/filing/0001140361-24-040650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.